PHVS Stock Recent News

Biotech stock Pharvaris plummeted Monday after the Food and Drug Administration placed a pair of its clinical studies on hold. The post Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried appeared first on Investor's Business Daily.

ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in two upcoming investor conferences in April: